| Source: |
| Type: |
| Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors. |
| 7721- | IP6, | Ins, | Effect of phytic acid and inositol on the proliferation and apoptosis of cells derived from colorectal carcinoma |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 7722- | IP6, | Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic |
| - | Review, | Var, | NA |
| 7642- | IP6, | Inositol Hexaphosphate Inhibits Proliferation and Induces Apoptosis of Colon Cancer Cells by Suppressing the AKT/mTOR Signaling Pathway |
| - | in-vitro, | CRC, | NA |
| 7645- | IP6, | Ins, | Anticancer Properties of Inositol Hexaphosphate and Inositol: An Overview |
| - | in-vitro, | Var, | NA |
| 7646- | IP6, | Ins, | Protection against cancer by dietary IP6 and inositol |
| - | Review, | Var, | NA |
| 7690- | IP6, | Ins, | Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application |
| - | Review, | Colon, | NA |
| 7691- | IP6, | Inositol Hexaphosphate Suppresses Growth and Induces Apoptosis in Prostate Carcinoma Cells in Culture and Nude Mouse Xenograft: PI3K-Akt Pathway as Potential Target |
| - | vitro+vivo, | Pca, | PC3 | - | in-vitro, | Pca, | C4-2B |
| 7701- | IP6, | Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-β-catenin-ABCG1 signaling pathway |
| - | vitro+vivo, | HCC, | Hep3B | - | NA, | NA, | MHCC-97H |
| 8280- | ISL, | ISL Induces Apoptosis and Autophagy in Hepatocellular Carcinoma via Downregulation of PI3K/AKT/mTOR Pathway in vivo and in vitro |
| - | vitro+vivo, | HCC, | SMMC-7721 cell |
| 7744- | ISL, | Isoliquiritigenin suppresses fatty acid synthesis and cancer cell migration in anaplastic thyroid carcinoma through AMPK/SREBF1 pathway |
| - | vitro+vivo, | Thyroid, | NA |
| 7745- | ISL, | Isoliquiritigenin inhibits colorectal cancer progression by targeting the FGFR4/FASN mediated lipid metabolism pathway |
| - | in-vitro, | CRC, | NA |
| 7748- | ISL, | GEM, | Isoliquiritigenin combined with gemcitabine inhibited lung cancer by suppressing JAK2/STAT3 signaling via lncRNA-p21/miRNA-4534 axis |
| - | in-vitro, | Lung, | NA |
| 7763- | ISL, | Harnessing Liquiritigenin: A Flavonoid-Based Approach for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 7786- | ISL, | Isoliquiritigenin exhibits anti-proliferative properties in the pituitary independent of estrogen receptor function |
| - | in-vitro, | Var, | NA |
| 7778- | ISL, | Isoliquiritigenin, a potent human monoamine oxidase inhibitor, modulates dopamine D1, D3, and vasopressin V1A receptors |
| - | Study, | Park, | NA | - | Study, | AD, | NA |
| 7777- | ISL, | Isoliquiritigenin induces HMOX1 and GPX4-mediated ferroptosis in gallbladder cancer cells |
| - | vitro+vivo, | Gall, | SGC996 |
| 9255- | ISO, IH, | Isorhamnetin Modulates Drug-Resistance-Related Biomarkers in Colon Cancer Cells |
| - | in-vitro, | Colon, | SW48 | - | in-vitro, | CRC, | HT-29 |
| 9254- | ISO, IH, | Isorhamnetin: what is the in vitro evidence for its antitumor potential and beyond? |
| - | Review, | Var, | NA |
| 9253- | ISO, IH, | Progress in the antitumor molecular mechanisms of Isorhamnetin |
| - | Review, | Var, | NA |
| 9252- | ISO, IH, | Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery |
| - | Review, | Var, | NA |
| 9251- | ISO, IH, | Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and Applications |
| - | Review, | Var, | NA |
| 9239- | ISO, IH, | Isorhamnetin suppresses colon cancer cell growth through the PI3K‑Akt‑mTOR pathway |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 |
| 9246- | ISO, IH, | Isorhamnetin inhibits migration and promotes apoptosis via modulation of oxidative stress, mitochondrial dysfunction, and the TIGIT/CD155 axis in 4T1 breast cancer cells |
| - | in-vitro, | BC, | 4T1 |
| 9245- | ISO, IH, | Autophagy inhibition enhances isorhamnetin‑induced mitochondria‑dependent apoptosis in non‑small cell lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 9244- | ISO, IH, | Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis |
| - | in-vitro, | Bladder, | 5637 |
| 9242- | ISO, IH, | Isorhamnetin Induces Melanoma Cell Apoptosis via the PI3K/Akt and NF- κ B Pathways |
| - | vitro+vivo, | Melanoma, | B16-BL6 |
| 9240- | ISO, IH, | Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen‑activated protein kinase kinase signaling pathways |
| - | in-vitro, | BC, | NA |
| 7882- | isoO, | Isoorientin triggers apoptosis of hepatoblastoma by inducing DNA double-strand breaks and suppressing homologous recombination repair |
| - | in-vitro, | Liver, | NA |
| 7859- | isoO, | Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 |
| 7853- | isoO, | Natural flavonoid isoorientin and its anticancer mechanisms: a systematic review |
| - | Review, | Var, | NA |
| 7885- | isoO, | Isoorientin from Gypsophila elegans induces apoptosis in liver cancer cells via mitochondrial-mediated pathway |
| - | in-vitro, | Liver, | HepG2 |
| 7873- | isoO, | Isoorientin attenuates doxorubicin-induced cardiac injury via the activation of MAPK, Akt, and Caspase-dependent signaling pathways |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Lung, | A549 |
| 7869- | isoO, | Apoptosis induction and inhibition of invasion and migration in gastric cancer cells by Isoorientin studied using network pharmacology |
| - | in-vitro, | GC, | HGC27 |
| 7866- | isoO, | Orientin and Cancer Suppression: Molecular Mechanisms and Synergistic Effects |
| - | Review, | Var, | NA |
| 7816- | ISQ, | Isoquercitrin Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | HGC27 |
| 7812- | ISQ, | Isoquercitrin promotes ferroptosis and oxidative stress in nasopharyngeal carcinoma via the AMPK/NF-κB pathway |
| - | vitro+vivo, | NPC, | CNE1 | - | in-vitro, | NPC, | HNE1 |
| 7847- | ISQ, | Research on the bioactivity of isoquercetin extracted from marestail on bladder cancer EJ cell and the mechanism of its occurrence |
| - | in-vitro, | Bladder, | NA |
| 7796- | ISQ, | Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway |
| - | vitro+vivo, | OS, | 143B | - | in-vitro, | OS, | U2OS |
| 7795- | ISQ, | The Flavonol Isoquercitrin Promotes Mitochondrial-Dependent Apoptosis in SK-Mel-2 Melanoma Cell via the PI3K/AKT/mTOR Pathway |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Nor, | HaCaT |
| 7848- | ISQ, | Review of anticancer mechanisms of isoquercitin |
| - | Review, | Var, | NA |
| 9193- | ITCs, | PEITC, | BITC, | SFN, | Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research |
| - | Review, | Var, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 7983- | itraC, | Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells |
| - | in-vitro, | Nor, | HUVECs |
| 7997- | itraC, | Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway |
| - | vitro+vivo, | SCC, | NA |
| 8010- | itraC, | Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells |
| - | vitro+vivo, | GC, | MKN45 |
| 8009- | itraC, | Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways |
| - | vitro+vivo, | Melanoma, | SK-MEL-28 | - | vitro+vivo, | Melanoma, | A375 |
| 7986- | itraC, | Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma |
| - | Trial, | BCC, | NA |
| 7994- | itraC, | From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer |
| - | Review, | Pca, | NA |
| 7985- | itraC, | Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking |
| - | vitro+vivo, | GBM, | U87MG | - | vitro+vivo, | GBM, | C6 |
| 8019- | itraC, | Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells |
| - | in-vitro, | Endo, | AN3CA | - | in-vitro, | Endo, | HEC-1A | - | in-vitro, | Endo, | HEC-50B | - | in-vitro, | Endo, | SNG-II |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:327 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid